



## Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

January 30, 2026

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan. 30, 2026-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 being held from February 11-12, 2026 in New York.

Details of the event are as follows:

Date: Thursday, February 12, 2026

Time: 2:00p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio's website at <http://www.adicetbio.com>. An archived replay will be available for 30 days following the presentation.

### **About Adicet Bio, Inc.**

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at <https://www.adicetbio.com>.

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20260130979631/en/>

### **Adicet Bio., Inc.**

#### **Investor and Media Contacts**

Anne Bowdidge

[abowdidge@adicetbio.com](mailto:abowdidge@adicetbio.com)

Penelope Belnap

Precision AQ

[penelope.belnap@precisionaq.com](mailto:penelope.belnap@precisionaq.com)

Source: Adicet Bio, Inc.